Next-generation vaccines and platform-based regulatory strategies to tackle emerging infectious diseases

Résumé

Emerging infectious diseases are increasing in Europe and require rapid, effective vaccination strategies. While conventional vaccines (inactivated and live attenuated) have proven effective, they are slow to develop and lack flexibility against evolving pathogens. Second- and thirdgeneration vaccines, including subunit, vector-based, DNA, mRNA, and saRNA technologies, offer improved safety, faster development, and greater adaptability. In particular, mRNA and saRNA platforms enable rapid antigen updates and scalable manufacturing. These technologies support platform-based regulatory approaches, where registered platforms accelerate approval of new vaccines. This paradigm shift significantly reduces development timelines and enhances responsiveness to emerging diseases, transforming vaccine development into a more agile and scalable system.